Table 1.
Baseline Clinical and Sociodemographic Characteristics of the Patients Included in the Neuropsychological Evaluations, Per Treatment Arm and for the Total Study Population
| MBVP (n = 60) | R-MBVP (n = 65) | Total (n = 125) | |
|---|---|---|---|
| Sex (n, % male) | 35 (58%) | 29 (45%) | 64 (51%) |
| Age (median, IQR) | 60 (55–66) | 61 (55–67) | 61 (55–66) |
| WHO performance score (n, %) | |||
| WHO 0 | 16 (27%) | 16 (25%) | 32 (26%) |
| WHO 1 | 28 (47%) | 33 (51%) | 61 (49%) |
| WHO 2 | 11 (18%) | 9 (14%) | 20 (16%) |
| WHO 3 | 5 (8%) | 7 (11%) | 12 (10%) |
| Comorbidities active at baseline (n, % ≥2) | 29 (48%) | 33 (51%) | 62 (50%) |
| Baseline IQ (median, IQR) | 93 (76–106) | 92 (77–106) | 93 (77–106) |
| Level of education (years of education; n, %) | |||
| Low (≤6) | 10 (17%) | 11 (17%) | 21 (17%) |
| Average (7–9) | 30 (50%) | 36 (55%) | 66 (53%) |
| High (10–18+) | 12 (20%) | 11 (17%) | 23 (18%) |
| Missing | 8 (13%) | 7 (11%) | 15 (12%) |
| Solitary lesion (n, %) | 35 (58%) | 32 (49%) | 67 (54%) |
| Missing/NA | 3 (5%) | 3 (5%) | 6 (5%) |
| Bilateral involvement (n, %) | 22 (37%) | 27 (42%) | 49 (39%) |
| Missing/NA | 3 (5%) | 3 (5%) | 6 (5%) |
| Deep structures involved (n, %) | 39 (65%) | 43 (66%) | 82 (66%) |
| Study drug exposure | |||
| HD-cytarabine (n, %) | 55 (92%) | 59 (91%) | 114 (91%) |
| WBRT (n, %) | 22 (37%) | 26 (40%) | 48 (38%) |
| Radiation boost given (n, %) | 10 (17%) | 16 (25%) | 26 (21%) |
| Intrathecal treatment given (n, %) | 6 (10%) | 6 (9%) | 12 (10%) |
| Baseline score for each neurocognitive domain | |||
| Neurocognitive domain | MBVP | R-MBVP | Total |
| Attention/executive functioning (mean, SD) | −0.52 (0.95) | −0.85 (1.03) | −0.70 (1.00) |
| Information processing speed (mean, SD) | −0.99 (1.74) | −1.29 (1.72) | −1.16 (1.72) |
| Memory (mean, SD) | −1.52 (1.20) | −1.70 (1.19) | −1.62 (1.19) |
| Motor speed (mean, SD) | −2.78 (3.11) | −4.43 (5.57) | −3.62 (4.57) |
| Impaired cognitive functioning (<1 SD) in at least one domain | 33/38 (87%) | 44/48 (92%) | 77/86 (90%) |
Abbreviations: HD-cytarabine, high-dose cytarabine; IQ, intelligence quotient; IQR, interquartile range; NA, not applicable in case of no brain lesion(s); WBRT, whole-brain radiotherapy.